Recent Updates
02
AnaptysBio enters antibody partnership with Gilead
May 2nd, 2012
Mandy Jackson
AnaptysBio is on a partnership roll: its agreement with Gilead Sciences, announcing on 1 May is its fourth new partnership in 2012 for the discovery of novel antibodies for partners.
AnaptysBio, a private firm based in San Diego disclosed neither the financial terms nor the disease areas of its Gilead deal, but AnaptysBio president and CEO Hamza Suria said the partnership would focus on areas in which Gilead has pipeline interest. Gilead is best known for its portfolio of antiviral drugs for HIV/AIDS and its development programs in hepatitis C therapies. It also has several therapeutics approved and in clinical development for cardiovascular, metabolic and respiratory conditions; cancer and inflammation; and liver disease.
(more…)
01
AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
May 1st, 2012
SHM-XEL platform to generate novel therapeutic antibodies
SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics. (more…)
21
Congress Is Wasting Money On Bad Defense Programs And Ignoring Good Ones
April 21st, 2012
By Mike “Mish” Shedlock
Business Insider
A close friend of mine since high school frequently writes for Foreign Affairs Magazine, the Small Wars Journal, and places like Janes’s Defence Weekly.
His latest article in the Small Wars Journal highlights compelling reasons that bigger, more expensive, weapons systems “borrowed from the end of World War II or the Cold War” are far too costly and are not even what is needed in today’s world. (more…)
13
AnaptysBio Makes Deal With Celgene For Antibodies
April 13th, 2012
By Lisa LaMotta
“The Pink Sheet” DAILY
AnaptysBio has gained another big partner in Celgene for its antibody discovery platform; bringing Celgene further into biologics.
(more…)
22
12 Investing and Business Gems from Avalon’s Kevin Kinsella
March 22nd, 2012
By Wade Rush
Xconomy
Current and former MIT students gathered at the Computer History Museum in Mountain View, CA, Tuesday night to hear one of San Diego’s most renowned venture investors, Avalon Ventures founder Kevin Kinsella, share insights from a long and adventurous career.
16
GHOST ship maker Juliet gets $9.67M
February 16th, 2012
by Rodney Brown
Mass High Tech
Juliet Marine Systems Inc., Portsmouth, N.H., developer of the GHOST stealth littoral defense ship, has taken in $9.67 million in the company’s first institutional funding round, according to an SEC filing. (more…)
06
ANAPTYSBIO ANNOUNCES NEW STRATEGIC ANTIBODY DISCOVERY ALLIANCES WITH TWO PHARMA PARTNERS
January 6th, 2012
SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company. The strategic alliance announced today with Novartis is AnaptysBio’s second collaboration with the Swiss-based pharmaceutical company and follows an initial partnership where AnaptysBio successfully delivered antibody candidates for Novartis’ development pipeline. (more…)